By Gilang Cahya 
In a significant breakthrough that promises to illuminate a disturbing trend in modern medicine, an international consortium of researchers, spearheaded by the University of California San Diego (UC San Diego), has pinpointed a likely microbial perpetrator behind the alarming surge in early-onset colorectal cancer: a potent bacterial toxin known as colibactin. This discovery offers a tangible explanation for a complex medical enigma that has baffled scientists and clinicians for years, as colorectal cancer rates inexplicably climb among younger demographics.
For decades, colorectal cancer was predominantly considered a disease affecting older adults, with the majority of diagnoses occurring after the age of 50. However, recent epidemiological data paints a starkly different picture. In at least 27 countries globally, the incidence of colorectal cancer in individuals under the age of 50 has approximately doubled every decade over the past twenty years. Projections indicate that if these trends persist, colorectal cancer could become the leading cause of cancer-related mortality among young adults by the year 2030, a sobering statistic that underscores the urgency of understanding its underlying causes.
The new study, published on April 23 in the prestigious journal Nature, meticulously analyzed 981 colorectal cancer genomes. These genomes were drawn from patients spanning both early- and late-onset disease categories and represented 11 countries with diverse colorectal cancer risk profiles. The research team, led by Professor Ludmil Alexandrov, a prominent figure in bioengineering and cellular and molecular medicine at UC San Diego and a member of the Moores Cancer Center, unearthed compelling evidence linking colibactin exposure to a distinct genetic signature imprinted on the DNA of colon cells. This signature, they propose, significantly elevates the risk of developing colorectal cancer before the age of 50.
The Genetic Fingerprint of Colibactin
Colibactin is produced by specific strains of Escherichia coli (E. coli), a bacterium commonly found residing in the human colon and rectum. While E. coli is a normal inhabitant of the gut microbiome, certain strains harbor the genetic machinery to synthesize colibactin, a toxin with a known capacity to induce DNA damage. The UC San Diego-led study provides the first robust evidence that exposure to this toxin, particularly in early childhood, leaves behind a recognizable pattern of DNA mutations.
"These mutation patterns are a kind of historical record in the genome, and they point to early-life exposure to colibactin as a driving force behind early-onset disease," explained Professor Alexandrov, who also holds a leadership role at the Sanford Stem Cell Fitness and Space Medicine Center. "This is a crucial step in understanding why so many young people are being diagnosed with this disease."
The research found that these colibactin-induced mutation patterns were a remarkable 3.3 times more prevalent in early-onset colorectal cancer cases – specifically among adults under 40 – compared to those diagnosed after the age of 70. Furthermore, the study observed a strong correlation between the prevalence of these mutation patterns and countries experiencing a high incidence of early-onset colorectal cancer, suggesting a geographical component to this microbial influence.
A Silent Colonizer: The Early Impact of Colibactin
Previous research, including earlier work from Alexandrov’s laboratory, had hinted at the role of colibactin, identifying colibactin-related mutations in approximately 10 to 15 percent of all colorectal cancer cases. However, those studies either focused exclusively on late-onset disease or failed to differentiate between early and late diagnoses. The current Nature publication represents a significant advancement by unequivocally demonstrating a pronounced enrichment of colibactin-related mutations specifically within the early-onset cohort.
The implications of this finding are profound, especially given the lack of clear risk factors in many young patients. Individuals diagnosed with early-onset colorectal cancer often present without a family history of the disease and exhibit few of the traditional risk factors associated with later-life development, such as obesity or hypertension. This diagnostic void has fueled speculation about potential environmental or microbial exposures playing a critical role, a hypothesis now strongly supported by this new research.
"When we started this project, we weren’t planning to focus on early-onset colorectal cancer," admitted study co-first author Marcos Díaz-Gay, formerly a postdoctoral researcher in Alexandrov’s lab. "Our original goal was to examine global patterns of colorectal cancer to understand why some countries have much higher rates than others. But as we dug into the data, one of the most interesting and striking findings was how frequently colibactin-related mutations appeared in the early-onset cases."
The study’s molecular timing analysis of the identified mutational signatures indicates that colibactin’s damaging effects are initiated early in tumor development. This aligns with prior research suggesting that these specific mutations can occur within the first decade of life. Critically, the research reveals that colibactin-related mutations account for approximately 15% of the so-called "APC driver mutations" in colorectal cancer. APC driver mutations are among the earliest genetic alterations that directly propel the development of cancer.
Professor Alexandrov elaborated on this critical point: "If someone acquires one of these driver mutations by the time they’re 10 years old, they could be decades ahead of schedule for developing colorectal cancer, getting it at age 40 instead of 60." This suggests that colibactin-producing bacteria may be silently colonizing children’s colons, initiating irreversible molecular changes in their DNA, and thereby laying the groundwork for cancer development long before any clinical symptoms manifest.
Building on a Foundation of Mutational Signature Research
This groundbreaking work is part of the Cancer Grand Challenges initiative, specifically the Mutographs team, which is funded by Cancer Research UK. It represents the latest milestone in an ongoing body of research championed by Alexandrov, Díaz-Gay, and their colleagues over several years. Their collective expertise lies in deciphering the intricate patterns of DNA mutations caused by various environmental exposures, including UV radiation and bacterial toxins, as well as lifestyle behaviors like smoking and alcohol consumption. Each of these factors leaves a unique genetic fingerprint, or mutational signature, in the genome, which can serve as a powerful tool to trace the origins of certain cancers.
Through a long-term collaboration involving UC San Diego, the International Agency for Research on Cancer in France, and the Wellcome Sanger Institute in the UK, made possible by Cancer Grand Challenges funding, the Mutographs team has already elucidated the mutational processes underlying esophageal, kidney, and head and neck cancers globally. The current findings on colorectal cancer further broaden the international understanding of cancer etiology through the lens of mutational signature analysis.
By systematically cataloging these mutational patterns across thousands of cancer genomes, researchers aim to identify novel causes of cancer that have historically evaded detection. "Not every environmental factor or behavior we study leaves a mark on our genome," Professor Alexandrov remarked. "But we’ve found that colibactin is one of those that can. In this case, its genetic imprint appears to be strongly associated with colorectal cancers in young adults."
Addressing the Global Rise and Future Directions
While the study provides strong evidence supporting the hypothesis of colibactin’s role in early-onset colorectal cancer, Professor Alexandrov cautioned that further research is essential to definitively establish causality. Nonetheless, the implications are far-reaching, prompting a cascade of new questions and potential avenues for intervention.
Key among these is understanding the pathways of childhood exposure to colibactin-producing bacteria. Researchers are keen to explore how these exposures occur and what strategies might be employed to prevent or mitigate them. Factors such as specific environments, dietary habits, or lifestyle behaviors that may promote colibactin production are also under investigation. Furthermore, the team is exploring how individuals might ascertain if they have acquired these cancer-promoting mutations.
The research team is actively pursuing several hypotheses. They are conducting further analyses to strengthen the correlation between colibactin and early-onset colorectal cancer risk. Additionally, they are investigating the potential of probiotics as a safe and effective means of eliminating harmful colibactin-producing bacterial strains from the gut microbiome. A significant development is the ongoing work to develop early detection tests that can analyze stool samples for the presence of colibactin-related mutations, offering a non-invasive screening option.
Beyond the immediate focus on colibactin, the team continues its global surveillance for other cancer-linked mutational signatures. Their recent Nature study also identified an increase in specific mutational signatures in colorectal cancers from certain countries, including Argentina, Brazil, Colombia, Russia, and Thailand. This finding suggests that localized environmental exposures may also contribute significantly to cancer risk in these regions, potentially paving the way for targeted, region-specific prevention strategies.
Dr. Díaz-Gay, who is now leading a new phase of this research at the Spanish National Cancer Research Center (CNIO) in Madrid, commented, "It’s possible that different countries have different unknown causes. That could open up the potential for targeted, region-specific prevention strategies."
The broader implication of this research, as highlighted by Professor Alexandrov, is a paradigm shift in our understanding of cancer origins. It suggests that many cancers may not be solely a consequence of adult lifestyle choices or age-related cellular decline, but rather could be deeply rooted in environmental or microbial exposures experienced in early life, long before a diagnosis is made.
"This reshapes how we think about cancer," Professor Alexandrov concluded. "It might not be just about what happens in adulthood — cancer could potentially be influenced by events in early life, perhaps even the first few years. Sustained investment in this type of research will be critical in the global effort to prevent and treat cancer before it’s too late." This comprehensive approach, combining genomic analysis with an understanding of microbial influences, offers a beacon of hope in the fight against a disease that is increasingly affecting the youngest among us.